What is recorded here?
Reported a randomized clinical comparison in HER2-overexpressing metastatic breast cancer in which adding trastuzumab to first-line chemotherapy improved measured clinical outcomes while identifying important cardiotoxicity.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.
Read the original work
- Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer
- Crossref record for trastuzumab metastatic-breast-cancer trial
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Dennis J. Slamon; Brian Leyland-Jones; Steven Shak; Hank Fuchs; Virginia Paton; Alex Bajamonde; Thomas Fleming; Wolfgang Eiermann; Janet Wolter; Mark Pegram; Jose Baselga; Larry Norton
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Documented mapping · Included in country comparison
Documented countries / regions: United States, Canada, Germany, Spain
Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.
English catalogue narrative
Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer
Reported a randomized clinical comparison in HER2-overexpressing metastatic breast cancer in which adding trastuzumab to first-line chemotherapy improved measured clinical outcomes while identifying important cardiotoxicity.
Scientific scope
The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Dennis J. Slamon; Brian Leyland-Jones; Steven Shak; Hank Fuchs; Virginia Paton; Alex Bajamonde; Thomas Fleming; Wolfgang Eiermann; Janet Wolter; Mark Pegram; Jose Baselga; Larry Norton
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.